Drug-drug interaction management with DDI-Predictor | Michel Tod, PharmD, PhD

International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018

Pharmacotherapy of Comorbities: Cancer Patients with HIV/AIDS | Michelle Rudek, PharmD, PhD

International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018

Drug-Drug interactions with targeted oncolytics (in particular PPIs and TKIs) | Ron Mathijssen

International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018

Clinical relevance of liquid biopsy in cancer patients | Catherine Alix-Panabières, PhD

International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018

The value of surrogate endpoints in the benefit-risk assessment of new drugs | Gabe Sonke, MD, PhD

International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018

How studies can be optimized by simultaneous use of PK/PD outcome measurement? | Alwin Huitema

International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018

Central and Eastern European Meeting on Viral Hepatitis and HIV 2018

Update on changes in Hepatitis B and C in CEE countries- Miłosz Parczewski, MD, PhD

Central and Eastern European Meeting on Viral Hepatitis and HIV 2018

Epidemiology of HIV Infection and Treatment in Europe- Teymur Noori, MSc

Central and Eastern European Meeting on Viral Hepatitis and HIV 2018

Country models: what has and what hasn’t worked- Nikoloz Chkhartishvili, MD, MS, PhD

Central and Eastern European Meeting on Viral Hepatitis and HIV 2018

Country models: what has and what hasn’t worked- Zahedul Islam, MBA

Central and Eastern European Meeting on Viral Hepatitis and HIV 2018

Hepatitis Delta: what are the new developments, what are the challenges?- Cihan Yurdaydin, MD

Central and Eastern European Meeting on Viral Hepatitis and HIV 2018

Treatment-experienced patients in Central and Eastern Europe – What needs to be done?- Viktor Aster, MD, PhD

Central and Eastern European Meeting on Viral Hepatitis and HIV 2018

HIV & women’s health: do we have any game changers here?- Mariana Mărdărescu, MD, PhD

Central and Eastern European Meeting on Viral Hepatitis and HIV 2018

Clinical Case Discussion: Switching HIV Therapy- Pavel Khaykin, MD

Central and Eastern European Meeting on Viral Hepatitis and HIV 2018

Clinical considerations in switching antiretroviral therapy- David Jilich, MD

Central and Eastern European Meeting on Viral Hepatitis and HIV 2018

Possible misclassification of HIV transmission between men: results of phylogenetic analysis- Natia Dvali

Central and Eastern European Meeting on Viral Hepatitis and HIV 2018

Real-life effectiveness of ledipasvir/sofosbuvir regimen and factors associated with retention in care among HIV/HCV co-infected PWID in Ukraine- Tetyana Kyrychenko

Central and Eastern European Meeting on Viral Hepatitis and HIV 2018

Spontaneous HCV clearance in HCV/HIV coinfected patients from AIDS Center Prague- Viktor Aster

Central and Eastern European Meeting on Viral Hepatitis and HIV 2018

Epidemiology of HIV in the Baltic countries (Estonia, Latvia, Lithuania)- Saulius Caplinskas

Central and Eastern European Meeting on Viral Hepatitis and HIV 2018

Critical assessment of the global epidemiology of HCV- Peter Ferenci, MD

Central and Eastern European Meeting on Viral Hepatitis and HIV 2018

Liver transplantation for HCV and HBV in The Czech Republic- Soña Frankova, MD, PhD

Central and Eastern European Meeting on Viral Hepatitis and HIV 2018

The EpiTer-2 database- Robert Flisiak, MD, PhD

Central and Eastern European Meeting on Viral Hepatitis and HIV 2018

Case Study: The changing IV drug use problem/pattern and what that means to the epidemic- Mojca Maticic, MD, PhD

Central and Eastern European Meeting on Viral Hepatitis and HIV 2018